We’ve been collaborating with the #Duchenne community for more than ten years and today on World Duchenne Day, we join them to raise awareness and inspire action that change the lives of families impacted by #DMD. To the Duchenne community, thank you for a decade of partnership.

This morning we shared a positive update from the ongoing RestorAATion-2 trial of WVE-006 in AATD, where we achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases and the first-ever demonstration of

Today we announce a positive update from our ongoing RestorAATion-2 trial of WVE-006 in alpha-1 antitrypsin deficiency. Read the press release: https://t.co/a1t6D7VB6e Join us at 8:30 AM ET for an investor webcast: https://t.co/0Z94zq54CE $WVE

At Wave, every day is #RNADay. For over a decade, we’ve been advancing the #RNA field, building the industry’s leading multimodal platform, PRISM, for developing RNA medicines. From editing to silencing to splicing RNA, our best-in-class chemistry is designed to unlock the broad

Today we announced our 2Q 2025 earnings update, including that we remain on track to share clinical data sets this year for the RestorAATion-2 trial for WVE-006 in #AATD, as well as INLIGHT for WVE-007 in #obesity. $WVE

On Wednesday, July 30, we will present our 1Q earnings update. Click below to register and listen to the webcast. $WVE

Wave’s success is built on our team’s drive, passion, and collaboration. Anthony Murabito, our VP of IT and Chief of Data Security, talks to @The_Swan_Group's Biotech Bytes podcast about how we think about talent management, the potential of AI, and more.

Attending the @AlphaFriend National Conference? Join us Saturday at 11:55 a.m. to learn about our #RNAediting platform and our RestorAATion-2 trial of WVE-006 for people with #AATD. #A1FNC25 #Alpha1

#ICYMI: This week we announced the appointment of Chris Wright, MD, PhD, as our Chief Medical Officer. Learn more about Dr. Wright and his role at Wave here: https://t.co/RGFuNxNvCA $WVE

Our President and CEO, @PaulBolno, will be participating in an analyst-led fireside chat at the @Jefferies Global Healthcare Conference on Wednesday, June 4. Save the date and register for the webcast below. #JefferiesHealthcare $WVE

Today we announced the appointment of Chris Wright, MD, PhD, as our Chief Medical Officer. Dr. Wright brings deep experience across a wide breadth of therapeutic areas and modalities and will guide development of Wave’s robust #RNA medicines pipeline. Click below for more. $WVE

Today we announced our 1Q 2025 earnings update, including progress advancing our clinical trials for WVE-007 in #obesity and WVE-006 in #AATD and highlighting our differentiated programs in #Duchenne and #HuntingtonsDisease. $WVE

Tomorrow, we will present our 1Q earnings update. Webcast registration here: https://t.co/A8i3xmcEHw $WVE

On Thursday May 8, we will present our 1Q earnings update. Click below to register and listen to the webcast. $WVE

We are pleased to announce positive data from the Phase 2 FORWARD-53 trial of WVE-N531, as well as our plans to file an NDA in 2026 for accelerated approval. Join us this morning at 8:30 AM ET for an investor conference call where we’ll discuss the results. $WVE

This morning we shared positive data from the Phase 2 FORWARD-53 trial of WVE-N531 in #Duchenne where we observed significant functional benefits and reversal of muscle damage after 48 weeks of dosing. Click below to more about these data. $WVE

This Saturday at the #CSHLNat meeting, Wave's Jack Godfrey will present on expanding therapeutic #RNAediting outside the liver, including to the lung and CNS. Learn more about @CSHL here: https://t.co/Y6xv4U2d6o

Thank you @HDYOFeed for a wonderful weekend in #Prague and the chance to connect with young people in the #HuntingtonsDisease community. We know that every #HD story is unique and we’re grateful to hear the diverse perspectives of youth from around the world. Having worked in HD

As we strive to develop impactful therapies for individuals facing life-changing conditions such as #HuntingtonDisease, we remain dedicated to consistently engaging with and learning from the community. Jamie joined us at Wave this week to share her #HD journey, including her

Our team helped @AlphaFriend celebrate their 30th anniversary at the annual Celtic Connection this past weekend! It was an inspiring and beautiful night dedicated to raising awareness and showing support for #Alpha1! #AATD #Alpha1Community